These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27783867)

  • 21. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
    Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
    Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
    Reid G; Pel ME; Kirschner MB; Cheng YY; Mugridge N; Weiss J; Williams M; Wright C; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; Brahmbhatt H; MacDiarmid JA; van Zandwijk N
    Ann Oncol; 2013 Dec; 24(12):3128-35. PubMed ID: 24148817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A catalogue of treatment and technologies for malignant pleural mesothelioma.
    Schunselaar LM; Quispel-Janssen JM; Neefjes JJ; Baas P
    Expert Rev Anticancer Ther; 2016; 16(4):455-63. PubMed ID: 26943000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma.
    Adusumilli PS; Chan MK; Hezel M; Yu Z; Stiles BM; Chou TC; Rusch VW; Fong Y
    Ann Surg Oncol; 2007 Jan; 14(1):258-69. PubMed ID: 17080237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy.
    Fukazawa T; Matsuoka J; Naomoto Y; Maeda Y; Durbin ML; Tanaka N
    Cancer Res; 2008 Sep; 68(17):7120-9. PubMed ID: 18757427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
    Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
    Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
    Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
    Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
    J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
    Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
    Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
    [No Abstract]   [Full Text] [Related]  

  • 33. Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.
    Ueno T; Toyooka S; Fukazawa T; Kubo T; Soh J; Asano H; Muraoka T; Tanaka N; Maki Y; Shien K; Furukawa M; Sakaguchi M; Yamamoto H; Tsukuda K; Miyoshi S
    Acta Med Okayama; 2014; 68(1):23-6. PubMed ID: 24553485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.
    Acuna SA; Ottolino-Perry K; Çako B; Tang N; Angarita FA; McCart JA
    Ann Surg Oncol; 2014 Jul; 21(7):2259-66. PubMed ID: 24719018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells.
    Iguchi K; Sakurai F; Tomita K; Katayama K; Yamaguchi T; Kawabata K; Tagawa M; Kawabata M; Shirakawa T; Mizuguchi H
    Cancer Gene Ther; 2012 Feb; 19(2):118-25. PubMed ID: 22076042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
    Yoo JY; Kim JH; Kwon YG; Kim EC; Kim NK; Choi HJ; Yun CO
    Mol Ther; 2007 Feb; 15(2):295-302. PubMed ID: 17235307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.
    Belin LJ; Ady JW; Lewis C; Marano D; Gholami S; Mojica K; Eveno C; Longo V; Zanzonico PB; Chen NG; Szalay AA; Fong Y
    Surgery; 2013 Sep; 154(3):486-95. PubMed ID: 23890748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADAM10 mediates malignant pleural mesothelioma invasiveness.
    Sépult C; Bellefroid M; Rocks N; Donati K; Gérard C; Gilles C; Ludwig A; Duysinx B; Noël A; Cataldo D
    Oncogene; 2019 May; 38(18):3521-3534. PubMed ID: 30651596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.